[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pediatric-solid-tumors\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pediatric-solid-tumors":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,44,73,95,119,146],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":20,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100632525","integration-of-adaptive-proton-therapy-in-pediatric-solid-tumors-and-hodgkins-lymphoma-100632525",false,"NCT07514819","Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma","Inclusion Criteria:\n\n* Participants diagnosed with solid tumors, including Rhabdomyosarcoma, Osteosarcoma, Ewing sarcoma, other sarcomas and carcinomas or also Hodgkin's lymphoma.\n* Participants who receive proton radiation therapy at St. Jude Children's Research Hospital.\n* Research participant or legal guardian\u002Frepresentative gives written informed consent.\n\nExclusion Criteria:\n\n* Participants who are not diagnosed with solid tumors or Hodgkin's lymphoma.\n* Participants who are diagnosed with Wilm's tumor or neuroblastoma\n* Participants who do not undergo proton therapy.\n* Participants who are prescribed equal or less than 5 fractions of proton therapy.\n* Participants with severe comorbid conditions that may impact imaging feasibility.\n* Inability to obtain written consent from research participant or legal guardian\u002Frepresentative.\n* Females of child-bearing potential cannot be pregnant or breast-feeding. Female participants \\>10 years of age or post-menarchal must have a negative serum or urine pregnancy test\n\nAll participants receiving proton therapy at St. Jude Children's Research Hospital will be screened for participation on this research protocol based on the Inclusion Criteria and the Exclusion Criteria. Qualified candidates will be selected during the consultation.","ALL",{"count":17,"type":18},100,"ESTIMATED","INTERVENTIONAL",[21],"NA","Pediatric patients receiving proton therapy for solid tumors or Hodgkin's lymphoma may experience anatomical changes during treatment that can affect proton therapy accuracy. This prospective single-arm study uses regular low-dose imaging to monitor these changes and adjust treatment plans as needed. Participants will receive weekly or every-other-week CT scans, with MRI when appropriate, to assess whether the original plan remains accurate. Treatment plans will be updated if tumor coverage decreases by more than 5% or if radiation dose to normal tissues increases by more than 10%; otherwise, the original plan will continue. The study aims to determine how often plan adjustments are needed and to identify which disease sites are most likely to experience significant anatomical changes during treatment.\n\nPrimary Objective:\n\n* Define the frequency of replanning necessary to ensure tumor coverage never falls below 95% (or 5% drop) of the prescribed daily dose in participants with intact (gross) tumors to keep the tumor control optimal throughout the multi-week treatment regimen.\n* Define the frequency of replanning necessary to ensure organs-at-risk (critical organs) do not deviate by more than 10% of the initially approved dose constraints to keep the normal tissue complication minimal throughout the multi-week treatment regimen.\n\nSecondary Objectives\n\n* Establish a cone beam CT (CBCT)-based framework for quantifying body surface changes throughout the treatment course. This goal will be achieved by developing a novel algorithm that detects and tracks external anatomical variations longitudinally, without requiring CBCT image enhancement, enabling precise assessment of daily participant setup consistency and anatomical stability.\n* Overcome daily CBCT quality limitations by generating synthetic CT images that accurately represent daily anatomy and support proton dose recalculation or verification planning. This goal will be achieved by developing a hybrid pipeline that integrates deep learning models with the deformable image registration algorithm, trained and validated on disease site-specific data. This will enable precise dose mapping and tissue density estimation, directly supporting adaptive planning decisions without the need of diagnostic- quality CT images.",[24,25,26,27,28,29,30],"Pediatric Solid Tumors","Rhabdomyosarcoma","Ewing Sarcoma","Osteosarcoma","Hodgkin Lymphoma","Bone Tumor","Soft Tissue Sarcoma","NOT_YET_RECRUITING","2026-06-30",{"date":34,"type":35},"2026-07-02","ACTUAL",{"date":37,"type":18},"2026-08",{"date":39,"type":18},"2031-08",{"name":41,"class":42},"St. Jude Children's Research Hospital","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":15,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":43},"100597165","tumor-lymph-node-mapping-100597165","NCT07054944","Tumor-Lymph Node Mapping","FEASIBILITY AND SAFETY OF INDOCYANINE GREEN (ICG) GUIDED SENTINEL LYMPH NODE MAPPING FOR PEDIATRIC SOLID TUMORS - T-LyM (Tumor-Lymph Node Mapping)","T-LyM","Inclusion Criteria:\n\n* Any pediatric patient (under the age of 18 years) being treated at the University of Rochester Medical Center, Department of Surgery.\n* Diagnosed with pediatric solid tumor\n* Scheduled to undergo lymph node sampling as part of their clinical management.\n\nExclusion Criteria:\n\n* Subjects with a history of iodide allergies.\n* Inability or unwillingness of research participant or parent\u002Flegal guardian to give written informed consent.\n* Currently pregnant.\n* Infants under 650 grams.\n* Patients with extensive prior surgery at the primary site or nodal basin expected to affect the lymphatic drainage.","1 Month","17 Years",{"count":55,"type":18},10,"OBSERVATIONAL","The purpose of this study is to assess the feasibility and safety of ICG-guided intraoperative lymphography for detecting sentinel lymph nodes (SLN) in pediatric patients with solid tumors who require retroperitoneal lymph node dissection\u002Fsampling.\n\nThis trial is a single-site cross-sectional study. The injection of ICG directly into lymphatics draining the primary tumor will take place at the time of operation after the patient is under anesthesia.",[24,25,59,60],"Sarcoma","Germ Cell Tumor",[62],"PEDIATRIC CANCER","RECRUITING","2026-04-20",{"date":66,"type":35},"2026-04-23",{"date":68,"type":18},"2026-04-13",{"date":70,"type":18},"2028-07-30",{"name":72,"class":42},"University of Rochester",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":15,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":43},"100611409","dissecting-tumour-microenvironment-in-solid-paediatric-tumour-to-improve-adoptive-cell-therapy-100611409","NCT07240207","Dissecting Tumour MicroenvirOnment in Solid Paediatric Tumour to Improve Adoptive Cell Therapy","MOST","Inclusion Criteria:\n\n* pediatric patients 0-18 years\n* affected by solid tumors\n\nExclusion Criteria:\n\n* patients over 18\n* non-solid malignancies","1 Day","18 Years",{"count":83,"type":18},44,"Pediatric solid tumors exhibit a low mutational burden, limited availability of neoantigens, and poor infiltration of tumor-infiltrating lymphocytes (TILs) within the tumor microenvironment (TME), characteristics that reduce the effectiveness of immunotherapies in children. However, pediatric tumors express a subgroup of antigens that can be exploited as targets. Stimulating the T lymphocyte response against these antigens could overcome immunosuppressive barriers. The adoption of therapies based on cytotoxic T lymphocytes (CTLs) represents a promising strategy.\n\nA total of 42 neoplasms were analyzed, including: 8 neuroblastomas, 7 sarcomas, 4 nephroblastomas, 1 renal carcinoma, 2 rhabdomyosarcomas, 5 lymphomas, 2 ovarian carcinomas, 4 teratomas, 2 thyroid tumors, and 7 other rare tumors. Primary cells from these tumors were preserved, resulting in the stabilization of 5 cell lines used for functional studies in vitro.\n\nCurrently, 4 tumor-specific CTL lines derived from healthy adult donors have been expanded; tumor antigen-specific T cells showed the ability to recognize and kill commercial tumor cell lines as well as stabilized pediatric tumor lines from osteosarcoma, nephroblastoma, and neuroblastoma. In particular, the G-Rex bioreactor enabled greater expansion of CTLs while maintaining a broad spectrum of specificity for most tumor antigens and a lymphocyte phenotype with an increased composition of early memory T cells, correlated with greater persistence in vivo.\n\nThe results demonstrate that the use of bioreactors represents a significant advancement in the production of CTLs specific for pediatric tumor antigens. The ability of CTLs derived from bioreactors to express early memory and activation markers makes them particularly promising for clinical applications, where persistence and efficacy are key factors.\n\nBased on the presented results, the analysis of in vivo persistence and cytotoxic capacities in preclinical models will be deepened, aiming to confirm the efficacy of the produced cells.\n\nThe main objective of the project is to develop expansion protocols for CTLs specific to pediatric tumor antigens, proposing innovative protocols for the ex vivo expansion of CTLs targeting pediatric tumor antigens.\n\nFinally, standardizing the large-scale process could be another necessary objective to translate these findings into practical clinical applications improving immunotherapy in pediatric cancer with evident benefits for affected children and care givers.",[24],"2025-11-19",{"date":88,"type":35},"2025-11-20",{"date":90,"type":35},"2023-01-19",{"date":92,"type":18},"2025-12-31",{"name":94,"class":42},"Fondazione IRCCS Policlinico San Matteo di Pavia",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":15,"minAge":101,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":19,"phases":105,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":43},"100485982","phase-1-clinical-trial-of-gaia-102-for-refractoryrelapse-neuroblastomas-and-other-malignant-pediatric-solid-tumors-100485982","NCT05608148","Clinical Trial of GAIA-102 for Refractory\u002FRelapse Neuroblastomas and Other Malignant Pediatric Solid Tumors","Inclusion Criteria:\n\n1. Patients who have been confirmed to have the following malignant tumor by histological examination\n\n   * cohort A : neuroblastoma or malignant solid tumor with pulmonary metastases, rhabdomyosarcoma, undifferentiated sarcoma, Ewing's sarcoma family, osteosarcoma, other cartilage sarcoma, nephroblastoma, hepatoblastoma, germ cell neoplasma, other rare solid tumor (except brain tumor and brain metastases) .\n   * cohort B : neuroblastoma.\n   * cohort C \\& D : neuroblastoma and other malignant solid tumors, rhabdomyosarcoma, Ewing's sarcoma family, hepatoblastoma.\n2. Undergoing the following treatment.\n\n   * cohort A \\& B : Patients who have the resistance for more than two treatment regimens, and the resistance for all standard regimens based on the guideline.\n   * cohort C \\& D : Patients with neuroblastoma who have completed the dinutuximab regimen and still have residual tumor. Patients with rhabdomyosarcoma, Ewing's sarcoma family, hepatoblastoma who have the resistance for more than two treatment regimens, and the resistance for all standard regimens based on the guideline.\n3. Patients who have medical history for serious side effect , allergy reaction with regards to concomitant drugs.\n4. Patients aged from 1years to 24 years at the time of obtaining consent.\n5. Patients with performance status(PS) over 50 (Lansky Performance Status Score less than 16 years old) or (Karnofsky Performance Status over 16 years old) at the time of obtaining consent.\n\nExclusion Criteria:\n\n1. Patients with brain metastases.\n2. Patients diagnosed with cancerous meningitis\n3. Patients who received allogeneic hematopoietic stem cell transplant.\n4. Patients with active autoimmune disease.","1 Year","24 Years",{"count":104,"type":18},61,[106],"PHASE1","Cohort A(GAIA-102 alone):\n\nConfirm the safety of GAIA-102 alone for refractory\u002Frelapse neuroblastoma or pediatric solid tumors with lung metastases, and decide recommended dose for Phase II.\n\nCohort B(GAIA-102 with Dinutuximab):\n\nConfirm the safety of GAIA-102 with Dinutuximab, Filgrastim, Teceleukin combination for refractory\u002Frelapse neuroblastoma and decide recommended dose for Phase II.\n\nCohort C(GAIA-102 with Nivolumab):Confirm the safety of GAIA-102(Follow the recommended doses in Cohort A) with Nivolumab.\n\nCohort D(GAIA-102 with Nivolumab, Teceleukin):\n\nConfirm the safety of GAIA-102(Follow the recommended doses in Cohort A) with Nivolumab, Teceleukin.",[109,24],"Refractory\u002FRelapse Neuroblastoma","2025-11-14",{"date":112,"type":35},"2025-11-18",{"date":114,"type":35},"2022-10-26",{"date":116,"type":18},"2027-08-25",{"name":118,"class":42},"Kyushu University",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":126,"enrollmentInfo":127,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":129,"conditions":130,"keywords":131,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":43},"100136733","molecular-analysis-of-solid-tumors-100136733","NCT01050296","Molecular Analysis Of Solid Tumors","MAST","Inclusion Criteria:\n\n* Must have a suspected or known diagnosis of neuroblastoma, osteosarcoma, Ewing sarcoma family of tumor or soft tissue sarcoma based on the initial diagnostic workup and evidence of gross disease amenable to excision. Specimens may be collected at some or all of the following time points: initial biopsy, bone marrow aspiration procedures, tumor resection, and at time of possible relapse.\n* Patients with a diagnosis of retinoblastoma based on initial diagnostic workup and who require enucleation may be enrolled if there is no active therapeutic or biologic protocol for retinoblastoma.\n* The patient or his\u002Fher legal guardian, as appropriate, must provide written informed consent within 30 days of the removal of the first collection of tissue\u002Fbone marrow\u002Fblood sample for this protocol.\n* The patient is being seen at St. Jude Children's Research Hospital or at a collaborating institution.\n* Patients must be less than or equal to 25 years old at the time of enrollment.\n\nExclusion Criteria:\n\n* Patient is known to be Hepatitis B, Hepatitis C and\u002For HIV positive.","25 Years",{"count":128,"type":18},1000,"This study will prospectively characterize the molecular, cellular and genetic properties of primary and metastatic neuroblastoma, osteosarcoma, retinoblastoma, Ewing sarcoma family of tumors, soft tissue sarcomas, adrenocortical tumors and liver malignancies. These cell isolates will be used for gene expression array analysis, genomic analysis by \\[SNP\\] single nucleotide polymorphism chip, array \\[CGH\\] comparative genomic hybridization and next generation sequencing, and \\[TEM\\] transmission electron microscopy analysis. Additionally cell lines and orthotopic xenografts will be created from the obtained tumor specimens.\n\nThe specificity of TCRs will be examined by comparing paired TCR from peripheral blood and tumor infiltrating CD4+ and CD8+ T cells. Epigenetic studies will be performed looking at the methylation profile of these cells and to investigate the anti-tumor T cell response both pre- and post-PD1 inhibition.",[24],[132,133,27,25,134,135,136,137],"Neuroblastoma","Retinoblastoma","Ewing sarcoma","Non-rhabdomyosarcoma soft tissue sarcoma","Adrenocortical tumors","Liver malignancies","2025-11-07",{"date":140,"type":35},"2025-11-12",{"date":142,"type":35},"2010-02-10",{"date":144,"type":18},"2026-09-30",{"name":41,"class":42},{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":15,"minAge":153,"maxAge":102,"enrollmentInfo":154,"targetDuration":4,"studyType":19,"phases":156,"briefSummary":157,"conditions":158,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":169},"100590617","development-and-application-of-intervention-program-to-improve-mental-health-and-quality-of-life-of-solid-tumor-survivors-and-caregivers-100590617","NCT06969742","Development and Application of Intervention Program to Improve Mental Health and Quality of Life of Solid Tumor Survivors and Caregivers","Development and Clinical Application of Intervention Program to Improve Mental Health and Quality of Life of Pediatric Solid Tumor Survivors and Caregivers, a Multicenter, Experimental Group, Pre-and-post Evaluation Intervention Study","Inclusion Criteria:\n\n* Those between the ages of 10 and 24, and diagnosed with pediatric solid tumor, who are undergoing treatment or survivors who have completed the treatment and the treatment end date is within 2 years.\n* Parent or legal guardian who is a primary caregiver to children and adolescent patient of acute-transitional phase.\n* Those whose cognitive ability is capable of verbal counseling and who agrees to the evaluation assessment.\n\nExclusion Criteria:\n\n* Those who disagree to participate as a research subject.\n* Those whose psycho-emotional state requires professional treatment or medical conditions precludes intervention.\n* Those undergoing treatment and children and adolescent survivors of acute-transitional phase, whose prior intelligence assessment FSIQ score is less than 70. However, if the GAI score is 70 or higher, participation is possible after the principal investigator's interview, with linguistic competence taken into consideration.\n\nElimination Criteria:\n\n* Those who withdraw consent of this research.\n* Those who have difficulty participating due to worsening of disease or decease of patient.","10 Years",{"count":155,"type":18},120,[21],"The research team will assess the psychological abilities like cognitive(how you think and figure things out) and psycho-social(the well-being at the intersection of the internal workings and external experience) functions of young patients who are diagnosed with solid tumor and their primary caregivers. After assessing the psychological abilities, the research team will provide counseling and educational sessions developed by the team. The sessions are provided on a 1:1 basis to each of the participants to verify whether the sessions helped to improve the quality of life, including mental health.",[24],"2025-05-12",{"date":161,"type":35},"2025-05-14",{"date":163,"type":35},"2023-12-27",{"date":165,"type":18},"2028-12-31",{"name":167,"class":168},"National Cancer Center, Korea","OTHER_GOV",3]